NCT01465230View on ClinicalTrials.gov

Maintenance Therapy: Lenalidomide Following Bendamustine and Rituximab Induction Therapy for Chronic Lymphocytic Leukemia

PHASE2TerminatedINTERVENTIONAL

Enrollment

2

Participants

Timeline

Start Date

March 31, 2012

Primary Completion Date

November 30, 2013

Study Completion Date

November 30, 2013

Conditions

Chronic Lymphocytic Leukemia

Interventions

DRUG

Maintenance lenalidomide

Daily maintenance treatment, oral lenalidomide

Trial Locations (1)

06519

Yale Cancer Center, New Haven

Sponsors

Collaborators (1)

Celgene Corporation

All Listed Sponsors

collaborator

Celgene Corporation

INDUSTRY

lead

Yale University

OTHER